We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Optical Clearing Method Preserves Critical Brain Tissue Structures

By LabMedica International staff writers
Posted on 30 Sep 2015
A recent paper described the use of a sorbitol-based optical clearing method that provides stable tissue preservation for immunochemical labeling and three-dimensional signal rendering.

Existing tissue clearing reagents contain chemical components that can compromise tissue structure, preventing reproducible anatomical and fluorescence signal stability.

To avoid tissue damage from the clearing reagent, investigators at the RIKEN Brain Science Institute (Saitama, Japan) spent the last five years improving their urea-based Scale clearing reagent. More...
The result, the sorbitol-based ScaleS reagent, was used to prepare tissues from the brains of mice with a genetic model of Alzheimer's disease.

Results published in the September 14, 2015, online edition of the journal Nature Neuroscience revealed that comparative benchmarking of contemporary clearing agents showed that ScaleS provided superior signal and structural preservation. ScaleS permitted optical reconstructions of aged and diseased brain in Alzheimer's disease models, including mapping of three-dimensional networks of amyloid plaques, neurons, and microglia, and multiscale tracking of single plaques by successive fluorescence and electron microscopy.

"The key ingredient of our new formula is sorbitol, a common sugar alcohol," said senior author Dr. Atsushi Miyawaki, senior team leader in cell function dynamics at the RIKEN Brain Science Institute. "By combining sorbitol in the right proportion with urea, we could create transparent brains with minimal tissue damage, that can handle both fluorescent and immunohistochemical labeling techniques, and is even effective in older animals."

"Clearing tissue with ScaleS followed by three-dimensional microscopy has clear advantages over two-dimensional stereology or immunohistochemistry," said Dr. Miyawaki. "Our technique will be useful not only for visualizing plaques in Alzheimer's disease, but also for examining normal neural circuits and pinpointing structural changes that characterize other brain diseases."

Related Links:

RIKEN Brain Science Institute



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Chromogenic Culture System
InTray™ COLOREX™ ECC
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.